New sits at the center of this dementia and brain health question.
Imagine a future where Alzheimer’s disease, a condition that affects millions worldwide, can be managed more effectively. Recent breakthroughs in Alzheimer’s research have brought hope to families and individuals dealing with this challenging condition. Two drugs, in particular, have been making headlines: lecanemab and donanemab. These medications are not cures, but they offer a promising way to slow down the progression of Alzheimer’s, giving people more time to enjoy life with their loved ones.
Lecanemab, known by its brand name Leqembi, was approved by the FDA in 2023. It works by targeting amyloid plaques, which are abnormal protein clumps that build up in the brains of people with Alzheimer’s. By reducing these plaques, lecanemab helps slow the rate of cognitive decline in patients with mild cognitive impairment or early Alzheimer’s.
Donanemab, approved in July 2024 and marketed as Kisunla, also targets amyloid but focuses on a specific type of amyloid called N3pG amyloid. Like lecanemab, it has shown potential in slowing down cognitive decline in patients with early Alzheimer’s. Both drugs have been shown to help people maintain their cognitive abilities for a bit longer, which can make a significant difference in their quality of life.
These advancements are part of a broader effort to understand and treat Alzheimer’s more effectively. Another promising area of research involves drugs originally developed for other conditions. For example, a drug called NU-9, initially designed for ALS, has shown potential in treating Alzheimer’s by addressing the underlying mechanisms of neurodegenerative diseases. While it’s still in the early stages of research, NU-9 offers hope that treatments could become more versatile and effective in the future.
The impact of these new drugs can be profound. For families, it means more time to share memories and experiences with their loved ones. For individuals with Alzheimer’s, it means a chance to maintain independence and cognitive function for longer. While there is still much work to be done, these developments mark a significant step forward in the fight against Alzheimer’s, offering a brighter future for those affected by this disease.
For more, see CDC — Alzheimer’s and Dementia.
